Background and Purpose-Current selection criteria for intra-arterial therapies in the anterior circulation use time windows of 8 hours. Modern neuroimaging techniques have identified individuals with salvageable penumbra who present beyond this timeframe. We sought to assess safety, procedural, and clinical outcomes of MRI or CT perfusion imaging-based endovascular therapy in patients with anterior circulation stroke treated beyond 8 hours from time last seen well. Methods-We conducted a multicenter retrospective review of consecutive patients meeting the following criteria: (1) acute proximal intracranial anterior circulation occlusion; (2) endovascular treatment initiated Ͼ8 hours from time last seen well; and (3) 
A concept fundamental to the rationale for instituting reperfusion therapy in acute ischemic stroke is that of mismatch between the ischemic core and penumbra. It is believed that the larger the mismatch, the higher the benefit of reperfusion. 1 After vessel occlusion, due to progressive collateral failure, there is continuous growth of the core at the expense of the penumbra. The aim of reperfusion therapy is to reverse this process by salvaging the penumbra and thereby limit the final infarct size. 2 Current selection criteria for reperfusion therapy use strict time windows. This is based on the assumption that the rate at which the ischemic process evolves in time is similar in all individuals. However, recent studies have shown that due to significant variability in collateral capacity, this process occurs at different speeds in different individuals. 3, 4 Consequently, the concept of a universal time window has increasingly been challenged and a physiological rather than chronological approach to patient selection for acute stroke interventions is gaining ground. 5 Given the particularly dismal natural history of untreated basilar occlusion, recanalization therapy in the posterior circulation beyond 8 hours is an acceptable paradigm in many centers. 6 Although relatively large case series exist with regard to endovascular therapy administered in the anterior circulation within 8 hours of symptom onset, 7 description of this approach beyond 8 hours is limited to single-center small case series. 8 -10 The aim of this study is to describe procedural and clinical outcomes of patients with acute stroke due to anterior circulation intracranial large vessel occlusions treated beyond 8 hours from time last seen well (TLSW) who were selected based on physiological data derived from imaging studies.
Materials and Methods
Eleven large regional referral stroke centers participated in this retrospective analysis of consecutive patients presenting with stroke as the result of acute proximal anterior circulation occlusion (internal carotid artery [ICA] and/or middle cerebral artery M1 and/or M2 segments) in whom endovascular therapy was performed beyond 8 hours from the TLSW on the basis of favorable MRI or CT perfusion (CTP) imaging characteristics. Patients with evidence of any intracranial hemorrhage or CT evidence of hypodensity involving greater than one third of the middle cerebral artery territory were excluded from further evaluation because they were not deemed eligible for treatment. Time of treatment initiation was defined as the time that the first angiographic run demonstrating the intracranial occlusion was performed. Patients who awoke with neurological deficits after going to sleep normal ("wake-up strokes") or were found with an unwitnessed stroke were included in the analysis as long as the intracranial occlusion was diagnosed beyond 8 hours from TLSW. Thus, there were 3 distinct categories in terms of type of presentation: (1) "witnessed onset stroke beyond 8 hours"; (2) "unclear time of onset strokes"; and (3) "wake-up strokes." Given the design of this study whose methodology involved retrospective data collection, no standardized imaging protocols were available to prospectively guide patient selection across all centers. In 38 cases, the imaging modality used for patient selection could not be determined. In 120 cases (61%), selection occurred based on CTP; in 53 (26%), selection occurred based on MRI; whereas in 26 (13%), selection occurred based on both CTP and MRI. Patients were selected based on visual inspection of MRI or CTP scans demonstrating mismatch between presumably irreversibly compromised brain (diffusion-weighted imaging or CTP-cerebral blood volume lesion) and inadequately perfused brain (cerebral blood flow, mean transit time, or time-topeak MRI or CTP maps). The amount of mismatch that qualified the patient for intervention was determined in each individual case by the treating stroke neurologist and interventionalist according to center-specific protocols and patient-specific characteristics. Based on common practice, however, across all centers, evidence of "infarct core" on the diffusion-weighted image or CTP-cerebral blood volume lesion involving greater than one third of the middle cerebral artery territory constituted a reason for exclusion from treatment.
Cases were identified through a search of prospectively acquired endovascular databases at each of these institutions. The following baseline and treatment variables were studied: age, gender, medical comorbidities, admission National Institutes of Health Stroke Scale (NIHSS), location of occlusion, TLSW to treatment, and treatment modality used (intra-arterial thrombolytic infusion, glycoprotein IIb/IIIa inhibitors, intra-and extracranial angioplasty and/or stenting, mechanical embolectomy with the MERCI or Penumbra devices). If occlusion of an intracranial vessel was identified, various recanalization strategies were used at the discretion of the operator (Supplemental Figure I ; http://stroke.ahajournals.org). Flow through the previously occluded vessel was graded using the Thrombolysis in Cerebral Ischemia or Thrombolysis in Myocardial Ischemia grading systems at each institution. Post-treatment imaging with CT or MRI was performed in all patients according to the local standard of care. Primary end points included the rates of postprocedure parenchymal hematomas (PH, including both PH-1 and PH-2 according to the European Cooperative Acute Stroke Study [ECASS] criteria), 11 successful recanalization (defined as Thrombolysis in Cerebral Ischemia or Thrombolysis in Myocardial Ischemia score Ն2), good functional outcome (defined as a modified Rankin Scale Յ2 at 3 months), and mortality. Functional outcomes were obtained in the outpatient clinic at follow-up or by telephone. In cases when outcomes after discharge were not available due to loss to follow-up, the discharge modified Rankin Scale was carried forward.
A prespecified subset of patients (Pre-DAWN Cohort) fulfilling the following criteria: (1) 
Statistical Analysis
Statistical analysis was performed using the STATA IC-10 software (StataCorp LP, College Station, TX). Descriptive statistics were performed. In univariate analysis, several variables of interest were correlated to the following binary outcome measures: good functional outcome and mortality. For each end point, all covariates with a probability value Ͻ0.2 were then entered into a multivariate stepwise logistic regression model. Significant association was considered for a probability value of Ͻ0.05.
Results
Two hundred thirty-seven patients were treated at 11 stroke centers. The pertinent clinical and treatment characteristics are summarized in Supplemental Table I . The mean age was 63.8Ϯ16 years (median, 66 years; range, 19 to 91 years) and the mean baseline NIHSS was 15Ϯ5.5 (median, 15; interquartile range, 12 to 19). Forty-nine percent (116) of the patients were males. The mean TLSW to treatment was 15Ϯ11.2 hours (median, 12 hours; interquartile range, 9.7 to 16). Information about the type of presentation was available in 77 patients because most centers equalized TLSW to "time of stroke onset" during data collection. Of these 77 patients, 63 (81%) had witnessed onset beyond 8 hours, 10 (13%) were "wake-up strokes," and 4 (5%) were "unclear time of onset strokes." Successful revascularization was achieved in 175 of 237 (73.84%) patients. PH occurred in 21 of 237 (8.86%) patients. Thirteen of the 21 (62%) patients who experienced PH died with only 2 patients (9.5%) achieving a good outcome at 3 months. The 90-day mortality rate for the overall cohort was 21.5% (51 of 237).
In univariate analyses, increasing age, history of atrial fibrillation, history of hypertension, lack of vessel recanalization, ICA terminus occlusion, and the development of PH were significantly associated with mortality. A significant difference in the rates of good functional outcome and mortality was seen based on recanalization status. Fifty-two percent of the recanalized patients versus only 23% of the nonrecanalized patients achieved a good functional outcome at 90 days (PϽ0.0001). Mortality rate at 90 days was 16% in the recanalized patients versus 38% in the nonrecanalized patients (PϽ0.0001; Figure) . We were not able to detect an association between good outcomes or PH and imaging selection modality (MRI versus CTP). Good outcomes were observed in 47% of patients selected based on CTP, 42% of patients selected based on MRI, and 53% of patients selected based on both modalities (Pϭnonsignificant). PH was observed in 9.1% of patients selected based on CTP, 11.3% of patients selected based on MRI, and 7.6% in patients selected based on both modalities (Pϭnonsignificant). Similarly, there was no significant association between presentation with "witnessed onset stroke beyond 8 hours" and good outcome or postprocedure PH.
A total of 169 patients fulfilled the pre-DAWN criteria. Pre-DAWN patients had similar age and baseline NIHSS scores as the patients in Pro-Urokinase (r-proUK) for Acute Cerebral Thromboembolism (PROACT) II and achieved similar rates of good outcome and mortality to the PROACT-II IA r-prourokinase-treated patients despite having more severe occlusions (ICA terminus and tandem occlusions included and M2 occlusions excluded) and significantly longer TLSW to treatment. In addition, the rates of symptomatic hemorrhage were also similar in the pre-DAWN and intra-arterial-treated PROACT-II patients ( Table 2) .
Discussion
The main finding of our study is that MRI or CTP imagingbased endovascular therapy in patients with acute ischemic stroke treated beyond 8 hours from TLSW can be performed with a safety profile that is similar to that observed in patients treated within 8 hours. Another observation is that the rate of favorable clinical outcomes with this approach appears to be similar to that seen when endovascular therapy is administered within 8 hours in patients selected based only on noncontrast CT. The advent of CTP in addition to diffusion-weighted imaging and MRI perfusion has triggered significant debate with regard to the optimal modality for patient selection. An important advantage of modern imaging technologies is the ability to more reliably outline the ischemic core, the most powerful imaging predictor of outcome in acute stroke due to large vessel occlusion. 12 Although core threshold values that predict favorable outcomes have not been prospectively established, retrospective studies indicate that a volume Ͻ70 mL on diffusion-weighted imaging or Alberta Stroke Programme Early CT Score Ͼ8 on CTP-cerebral blood volume maps is predictive of favorable outcomes. 13, 14 Studies investigating the use of MRI or CTP as a selection tool to extend the time window for intravenous thrombolysis have been typically based on visual inspection of the pretreatment imaging revealing a substantial mismatch between irreversibly injured brain and brain that is threatened but still viable. De facto this translates into determining a small core in the presence of a large perfusion deficit. Despite its strong foundation, this physiological approach to patient selection has not yet been validated by randomized clinical trials. Indeed, a recent pooled analysis of the Desmoteplase in Acute Ischemic Stroke Trial (DIAS), DIAS II, Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS), Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE), and Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) trials involving a total of 502 mismatch patients who were thrombolyzed beyond 3 hours failed to confirm a benefit of mismatch-based delayed intravenous thrombolysis. 15 Several factors might have contributed to these findings. First, mismatch is not equal to penumbra because it often incorporates a region of "benign oligemia" that will not evolve into core even in the absence of reperfusion. 16 Second, the aforementioned studies included patients with both distal and proximal arterial occlusions. This represents a challenge on both ends. Intravenous thrombolysis recanalizes only 10% to 30% of the proximal arterial occlusions. 6 Patients with distal occlusions on pretreatment imaging likely have a high rate of spontaneous reperfusion and/or good outcomes even in the absence of any intervention. Finally, thrombolysis carries the risk of symptomatic intracranial hemorrhage, which may further attenuate the benefits of reperfusion therapy. The reasons these studies may have limited relevance to our results are related to the fact that we only included patients with large vessel occlusion as well as to the fact that we used a treatment modality that is associated with higher rates of reperfusion. 7 Indeed, the aforementioned meta-analysis of the mismatchbased delayed thrombolysis trials demonstrated that favorable outcomes were greater for mismatch patients who were successfully reperfused. 15 Nonetheless, nonstandardized visual inspection of diffusion-weighted images or perfusion scans is subject to highly variable interpretation with regard to the presence and extent of mismatch, especially because thresholds that define reversible and irreversible ischemia both on MRI and (to a greater extent) on CTP have not been clearly established. Future prospective studies addressing these questions should use core and penumbra thresholds obtained quantitatively and validated by prospective studies.
A recent study investigating the benefit of intra-arterial thrombolytic therapies in acute ischemic stroke has established a clear relationship between time from stroke onset to angiographic reperfusion and good outcomes. 17 To that regard, at a first glance, our results seem to contradict these findings. We do, however, believe that this is not the case because this study enrolled only patients presenting very early (within 3 hours). Furthermore, the only imaging selection criterion for this study was a noncontrast head CT ruling out intracranial hemorrhage or a large hypodensity. Therefore, when patients are treated very early in the course of a stroke, and selection of patients occurs on the basis of a plain CT, there is a strong association between time to reperfusion and outcome. However, this does not discard the fact that at later points in time, there are patients with favorable physiology who may benefit from reperfusion. It has been shown that the earlier the time point in the course of acute cerebral ischemia, the higher the likelihood of mismatch. 16 However, in the setting of large vessel occlusion, many patients will have a significant mismatch even in the 9-to 24-hour window. 3 From that standpoint, in the ultraearly stages of ischemia (within 3 hours), a noncontrast head CT as imaging selection criteria may be sufficient because the majority of patients will have favorable physiology and the additional time requirement to obtain more sophisticated imaging studies may not be justified. As patients present further out in time with respect to symptoms onset, the likelihood of favorable physiology diminishes and therefore advanced MR/CTP techniques may become necessary. At later time windows, therefore, time appears to diminish its relevance as a selection tool. Although there is general consensus that information regarding tissue viability is required for appropriate patient selection, the superiority of the more expensive and time-consuming MRI or CTP techniques over expertly interpreted plain CT in conjunction with the clinical examination (CT-clinical mismatch) as a selection tool for endovascular therapy is not yet proven and still a matter of debate.
The retrospective nature represents the major limitation of our study. However, the validity of our results is supported by the fact that factors predicting good outcomes in our study are similar to the ones observed in trials enrolling patients within 8 hours in which successful revascularization, age, and baseline stroke severity were found to be the most powerful predictors of favorable outcomes. 18 Information about the distinct types of presentation was only available in a limited number of patients. Although we could not find any significant difference in our analysis, it is likely that patients with "unclear time of onset strokes" and "wake-up strokes" will behave differently from patients with "witnessed onset stroke beyond 8 hours" because in the first 2 categories, the true time of onset may be significantly closer to the time point at which the treatment was administered. However, it may also be the case that in the setting of similar physiological imaging signatures, the type of presentation is less relevant in defining outcomes after successful reperfusion. As discussed, the lack of standardization of the imaging protocol represents another important limitation of the current analysis. These limitations should be addressed in future prospective studies. Another major shortcoming of our study with respect to its ability to assess efficacy of the intervention used is the lack of a control group. Although outcomes obtained in our group of patients compare favorably with historical controls from randomized intra-arterial trials ( 7 the natural history of stroke due to large vessel occlusion in patients with small ischemic core volumes presenting beyond 8 hours from TLSW is unknown. Because lower core volumes at presentation are known to carry a more favorable prognosis both in patients who recanalize and in those who do not recanalize, 12 it is likely that outcomes in this group of patients may be more benign than in patients presenting with same vascular occlusion site within shorter time windows. Nevertheless, the presence of a severe clinical deficit as evidenced by a median NIHSS of 15 in our group of patients coupled with the presence of significant perfusion deficit suggest that in most of the patients described here, stroke progression with consequent worsening neurological status or lack of improvement would have constituted the more likely outcome as illustrated by the highly significant differences in the rates of clinical outcomes according to revascularization status in our cohort (Supplemental Figure II) . The comparison of the Pre-DAWN Cohort with the PROACT-II Trial further supports our hypothesis. However, given the uncertainties with regard to the fate of nontreated patients who have a similar clinical and imaging presentation to the patients described in the present study, it is imperative that prospective, randomized data are generated before this approach can be recommended as a matter of routine clinical care. Therefore, our results should be interpreted as hypothesis-generating and may aid in the design of a randomized trial comparing recanalization therapies with conservative management, which is necessary to prove superiority of this approach over medical therapy alone. G. white arrow) with complete sparing of the previously described territory at risk. At 90 days posttreatment, the NIHSS was down to 4 and the mRS was 2.
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